Our SOS for Kids with Eczema campaign is in full swing. This is a national campaign which is calling for equitable access to dupilumab (Dupixent®) for children aged six months to 11 years living with severe eczema. Although this medicine has been available on the PBS for Australians aged 12 years and older for the past five years, younger children remain without subsidised access despite significant unmet clinical need.
The response from families across Australia has been both strong and deeply meaningful, with many sharing their lived experience to help illustrate the substantial burden severe eczema places on children and their families. These stories and insights are critical in building understanding among federal decision-makers ahead of the 20 May PBAC submission deadline.
For healthcare professionals interested in learning more about Dupixent®, we encourage you to read our blog written for families and the published article by Kim et al. (2026), Dupilumab’s real-world efficacy and safety across age groups for children and adolescents with paediatric atopic dermatitis (Australasian Journal of Dermatology), which offers valuable Australian clinical insights into the effectiveness and safety of dupilumab.
Submissions from treating clinicians carry significant weight in PBAC considerations and can help ensure both clinical need and patient impact are clearly understood.
2026 is shaping up to be a significant year for our small team as we continue to attend the Health Ed Conferences across Australia, sharing evidence-based resources to support you and your patients in eczema care and management.
Also in this newsletter, you will find practical information on chronic hand eczema and important updates.
Our SOS for Kids with Eczema campaign is in full swing. This is a national campaign which is calling for equitable access to dupilumab (Dupixent®) for children aged six months to 11 years living with severe eczema. Although this medicine has been available on the PBS for Australians aged 12 years and older for the past five years, younger children remain without subsidised access despite significant unmet clinical need.
The response from families across Australia has been both strong and deeply meaningful, with many sharing their lived experience to help illustrate the substantial burden severe eczema places on children and their families. These stories and insights are critical in building understanding among federal decision-makers ahead of the 20 May PBAC submission deadline.
For healthcare professionals interested in learning more about Dupixent®, we encourage you to read our blog written for families and the published article by Kim et al. (2026), Dupilumab’s real-world efficacy and safety across age groups for children and adolescents with paediatric atopic dermatitis (Australasian Journal of Dermatology), which offers valuable Australian clinical insights into the effectiveness and safety of dupilumab.
Submissions from treating clinicians carry significant weight in PBAC considerations and can help ensure both clinical need and patient impact are clearly understood.
2026 is shaping up to be a significant year for our small team as we continue to attend the Health Ed Conferences across Australia, sharing evidence-based resources to support you and your patients in eczema care and management.
Also in this newsletter, you will find practical information on chronic hand eczema and important updates.
